Predictive Oncology Announces $7.2M Registered Direct Offerings
Predictive Oncology Inc. (NASDAQ:POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine
Predictive Oncology Q1 EPS $(0.05) Up From $(0.11) YoY
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.05) per share. This is a 54.55 percent increase over losses of $(0.11) per share from the same period last year.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Predictive Oncology Reports Prelim. Results Of Its Discovery 2021 Program: Its Helomics Unit Showed Proprietary AI Porogram CoRE Could Identify Potential New Chemo Drug Uses
Predictive Oncology Inc. (NASDAQ:POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial
Predictive Oncology Q3 EPS $(0.08) Up From $(0.46) YoY, Sales $313.66K Down From $480.76K YoY
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.08) per share. This is a 82.61 percent increase over losses of $(0.46) per share from the same period last year. The company reported $313.66 thousand
20 Stocks Moving in Monday’s Pre-Market Session
Gainers
Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading.
